Integra LifeSciences names Stuart Essig CEO, Michael McBreen chief commercial officer
Integra LifeSciences appointed Stuart Essig as President and Chief Executive Officer effective May 1, 2026, succeeding Mojdeh Poul, whose employment ended April 30, 2026. Essig remains Chairman of the Board, and the company said this is not an interim role and it does not intend to start a CEO search. The filing also names Michael McBreen as Chief Commercial Officer, a newly created role that gives him oversight of both divisions and the global commercial structure.
Key points
- Stuart Essig, 64, becomes President and CEO effective May 1, 2026, and stays as Chairman; he succeeds Mojdeh Poul, whose separation date was April 30, 2026.
- Essig's employment agreement sets a $1,075,000 annual base salary and a target bonus of 125% of base salary, with one-time equity awards of $4,000,000 in RSUs and $4,000,000 in options.
- Poul will receive a lump sum of $566,526, subject to signing a release, covering unvested RSU cash-out and a pro rata 2026 bonus.
- Michael McBreen becomes Chief Commercial Officer effective May 1, 2026, with a $660,000 base salary, a 90% target bonus and a $1,000,000 promotion award.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:59 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.